Latest Posts

27

Jun 23

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to...
Read More

9

Feb 23

AI supports targeted therapy recommendations fortumor diseases – BMBF funds joint research projectat University Medical Center Mainz with 2.53 millionEuros

The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

Innoplexus signs MoU to provide academic license for its iPlexus platform to Regional Cancer Centre, Gwalior, India

Innoplexus is proud to announce our collaboration with the Regional Cancer Centre, Gwalior. Innoplexus has executed an MoU to provide an academic license for its iPlexus platform to RCC, Gwalior, India. The academic license allows doctors and researchers with free access to iPlexus. Doctors and researchers will be able to gain insights into the latest advancements in research and trials related to cancer.

Featured News

New app for cancer patients

Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…